Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Regeneron Pharmaceuticals (REGN)

Regeneron Q2 2025 revenue rises 4% to $3.68 billion; GAAP EPS up 3% to $12.81

Positive Impact 3 of 5 earnings Written later

Regeneron reported second quarter 2025 total revenues of $3.68 billion, up 4% from a year earlier, and GAAP earnings per diluted share of $12.81, up 3%. GAAP net income fell 3% to $1.39 billion, and the company raised its full-year 2025 GAAP effective tax rate guidance to 11%–13%.

Key points

  • Total revenues $3.68 billion, up 4%; GAAP net income $1.39 billion, down 3%
  • Non-GAAP EPS $12.89, up 12%; GAAP EPS $12.81, up 3%
  • 2025 GAAP effective tax rate guidance raised to 11%–13% from 9%–11%; non-GAAP tax rate guidance unchanged at 11%–13%
  • Company expects delays to pending FDA approvals for EYLEA HD with August 2025 PDUFA dates; FDA issued a Complete Response Letter for odronextamab on July 30, 2025

The filing

CompanyRegeneron Pharmaceuticals (REGN)
Form8-K, current report
Filed with the SECAug 1, 2025, 6:49 AM ET
Accession number0000872589-25-000017

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 01, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.